Eric Mark Green - Aug 8, 2023 Form 4 Insider Report for WEST PHARMACEUTICAL SERVICES INC (WST)

Role
President & CEO, Director
Signature
Ryan Metz as Agent for Eric M. Green
Stock symbol
WST
Transactions as of
Aug 8, 2023
Transactions value $
-$14,500,820
Form type
4
Date filed
8/10/2023, 02:50 PM
Previous filing
Jul 5, 2023
Next filing
Oct 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction WST Common Stock Options Exercise $2.87M +50K +37.15% $57.38* 185K Aug 8, 2023 Direct F1
transaction WST Common Stock Sale -$390K -1K -0.54% $389.62 184K Aug 8, 2023 Direct F2
transaction WST Common Stock Sale -$1.76M -4.5K -2.45% $392.16 179K Aug 8, 2023 Direct F2, F3
transaction WST Common Stock Sale -$2.77M -7.06K -3.94% $393.13 172K Aug 8, 2023 Direct F2, F4
transaction WST Common Stock Sale -$3.28M -8.33K -4.84% $394.17 164K Aug 8, 2023 Direct F2, F5
transaction WST Common Stock Sale -$3.04M -7.68K -4.69% $395.07 156K Aug 8, 2023 Direct F2, F6
transaction WST Common Stock Sale -$2.65M -6.7K -4.29% $396.13 149K Aug 8, 2023 Direct F2, F7
transaction WST Common Stock Sale -$2.99M -7.53K -5.04% $397.18 142K Aug 8, 2023 Direct F2, F8
transaction WST Common Stock Sale -$438K -1.1K -0.78% $397.90 141K Aug 8, 2023 Direct F2, F9
transaction WST Common Stock Sale -$39.9K -100 -0.07% $398.87 141K Aug 8, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction WST Stock Option (Right to Buy) Options Exercise $0 -50K -33.75% $0.00 98.1K Aug 8, 2023 Common Stock 50K $57.38 Direct F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in 2025, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 5/5/2023.
F10 This option is fully vested.
F2 This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 5/5/2023. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person.
F3 The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $391.59 to $392.57, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.
F4 The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $392.625 to $393.60, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.
F5 The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $393.64 to $394.63, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.
F6 The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $394.65 to $395.60, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.
F7 The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $395.73 to $396.67, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.
F8 The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $396.73 to $397.62, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.
F9 The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $397.73 to $398.17, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.